Probiotix Health PLC - Grant of Options
Announcement provided by
ProBiotix Health Plc · PBX20/02/2025 07:01
20 February 2025
ProBiotix Health plc
("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")
Grant of Options
ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that options ("Options") have been granted over a total of 9,050,000 ordinary shares of 0.05p each in the Company ("Ordinary Shares") to Steen Andersen, Chief Executive of ProBiotix, and certain other key employees of the Company.
The options were granted on 19 February 2025 with an exercise price of 9.5p per share. The Options may be exercised within 10 years from the date of their grant, subject to satisfaction of commercially oriented performance criteria, which includes significant revenue targets.
Option holders can only exercise Options once these conditions have been met. This ensures a continued focus on commercial revenues and shareholder value creation.
For further information, please contact:
|
ProBiotix Health plc |
https://probiotixhealth-ir.com/ |
|
|
investors@probiotixhealth.com |
|
Steen Andersen, Chief Executive Officer Miles Nolan, Investor Relations |
|
|
Peterhouse Capital Limited |
|
|
Mark Anwyl Duncan Vasey
|
Tel: 020 7220 9793 |
|
|
|
This announcement contains information which, prior to its disclosure, was considered inside information for the purposes of the UK Market Abuse Regulation and the Directors of the Company are responsible for the release of this announcement.
Notes to Editors:
ProBiotix is a life sciences company that develops probiotic formulations to support cardiometabolic health. Since its formation, ProBiotix has become recognised as a global leader in microbiome modulating probiotics for use in food supplements and nutraceuticals.
The Company has a unique approach; discovering ground breaking probiotics, ensuring their benefits through robust science, and bringing to market effective finished probiotic-based products for human health across the globe.
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. |
||
|
1 |
Details of the person discharging managerial responsibilities / person closely associated |
|
|
a) |
Name |
Steen Andersen |
|
2 |
Reason for the notification |
|
|
a) |
Position/status |
Chief Executive Officer |
|
b) |
Initial notification /Amendment |
Initial |
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer, or auction monitor |
|
|
a) |
Name |
ProBiotix Health plc |
|
b) |
LEI |
98450048683CF0388C30 |
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
|
a) |
Description of the financial instrument, type of instrument Identification code |
ordinary shares of 0.05p each
ISIN: GB00BLNBFR86 |
|
b) |
Nature of the transaction |
Grant of Options |
|
c) |
Price(s) and volume(s) |
5,000,000 ordinary shares @ 9.5p per share |
|
d) |
Aggregated information - Aggregated volume - Price |
n/a |
|
e) |
Date of the transaction |
19 February 2025 |
|
f) |
Place of the transaction |
n/a |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
